News | August 03, 2022
Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
The company was directed to submit a plan of compliance by July 15, 2022
Domestic devices are usually preferred over imported medical devices in the national or regional procurement.
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Tislelizumab is now approved in nine indications in China
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
The drug will be available in 600 hospitals and 105 DTPs
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Subscribe To Our Newsletter & Stay Updated
